Method development, qualification and validation are at the core of our service portfolio. From product characterization to first-in-human to later stages of your drug development/approval cycle, we can support assay development and technology transfer, as well as method qualification and validation for GMP release and long-term stability studies of your drug substances and drug products.

Frontage offers extensive experience and advanced technology in biomarker assay development, validation, and testing, adhering to CAP, CLIA, GLP, and GCLP standards.

Fascin is an actin-bundling protein that has been linked to tumor cell migration, invasion, metastasis, disease progression and mortality, thus serving as a novel cancer biomarker. In this paper, we develop and validate an LC-MS/MS method for the quantification of fascin proteins in human serum.